ArticleVirus genes2025
Regulation of type I interferon factor secretion via the TLR3 signaling pathway after PRV infection of mouse trigeminal ganglion cells.
Article in Virus genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Divergent Strategies in Innate Immune Evasion: A Comparative Review of Three Alphaherpesvirus Subfamily Members-PRV, HSV-1, and VZV.Transboundary and emerging diseases · 2026Review
- Immune functions of avian erythrocytes: a comprehensive review from basic biology to pathogen-induced responses.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study investigates the effects of pseudorabies virus (PRV) infection on the antiviral immune signaling pathway and type I interferon factors in mouse trigeminal ganglion (TG) cells. The experiment involved inoculating TG primary cells with PRV and intranasally infecting mice. The results indicated that PRV infection of mouse TG primary cells led to alterations in the gene and protein expression of TLR3, TRIF, TBK1, and IRF3, while inhibiting the expression of IκBα protein in the later stages of infection. Additionally, the phosphorylation of IRF3 and IκBα was induced both in vivo and in vitro. Following PRV infection, the expression of IFN-α was up-regulated in the supernatant, whereas its expression was down-regulated in the cell lysates and mouse TG. To further investigate the role of TLR3 in the IRF3 signaling pathway and type I interferon factors, siRNA was employed to interfere with TLR3 expression in TG cells. Western blot analysis was conducted to assess the expression of TLR3 signaling pathway-related proteins and the secretion of IFN-α following the interference. The findings demonstrated that siTLR3 effectively reduced TLR3 protein expression in TG cells and concurrently modulated the secretion of type I interferon factors via the TLR3-TRIF-TBK1-IRF3 signaling axis. Furthermore, PRV infection was shown to induce TLR3 expression in both mouse TG primary cells and mouse TG, thereby activating the TLR3-TRIF-TBK1-IRF3 signaling axis to regulate the antiviral immune response in TG cells, while simultaneously inhibiting IFN-α expression within TG cells and TG through the TLR3 signaling pathway. These experimental results elucidate the antiviral immune mechanism associated with the TLR3 signaling pathway following PRV infection of mouse TG cells, offering new insights into the immune evasion strategies employed by PRV.
Indexed as
Identifiers
40616737What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.